Uveitis Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent and Other Developments

The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates, of which five drug candidates are in Phase III stage of development, seven drug candidates are in Phase II stage, three drug candidates are in Phase I, 15 drug candidates are in Pre-Clinical stage and three drug candidates are in Discovery stage. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss.

Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis

As per the findings of the research, around 37.0% of active drug candidates of uveitis pipeline are being developed to be administered by topical route, 12.0% are being developed by intravitreal route and 18.0% are to be administered by other routes such as oral, subcutaneous and intravenous. Route of administration of around 33.0% active drug candidates of uveitis pipeline is not disclosed.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis/report-sample

The research also found that various companies received grants for the development of uveitis therapeutics pipeline. In March 2017, Elasmogen Ltd. received a Biomedical Catalyst Grant from the U.K. innovation agency, Innovate UK and matching investment from Deepbridge Capital and Scottish Investment Bank (the investment arm of Scottish Enterprise) for developing ELN-21 and ELN-22 to be used in topical treatment of ocular disease. In August 2015, TxCell SA received a grant from French government’s Unique Interministerial Fund (FUI) to the TRUST project (TRegs in Uveitis STudy). The grant would be used to process and support clinical development of Col-Treg.

Some of the key players developing drugs for the treatment of uveitis include Alcon Research, Ltd., Enzo Biochem Inc., Mitotech, SA, EyeGate Pharmaceuticals, Inc., Aldeyra Therapeutics, Inc., pSivida Corp. and Santen Inc.

Designed by CyFocus.com
Powered by CyFocus.net